Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report detailing significant changes within its board of directors and executive leadership. Notably, the company announced the retirement of its Chief Financial Officer, Robert E. Landry, who has served in that capacity since 2013. Mr. Landry plans to retire in February 2024, and the company has appointed Christopher Fenimore, currently Senior Vice President, Controller, as his successor, ensuring a smooth transition in financial leadership. In addition to the CFO transition, Regeneron has elected two new independent directors to its Board: Dr. Kathryn Guarini and Dr. David P. Schenkein. These appointments are intended to fill existing vacancies and strengthen the Board's expertise. The report also discloses the departure of Dr. Marc Tessier-Lavigne as a director due to potential conflicts arising from increased involvement with other companies. These leadership changes, while significant, are presented as strategic moves to ensure continued strong governance and financial oversight at Regeneron.
Key Highlights
- 1Robert E. Landry, EVP, Finance and CFO, announced his intention to retire in February 2024 after a decade in the role.
- 2Christopher Fenimore, currently Senior Vice President, Controller, is appointed as the successor CFO, effective upon Mr. Landry's retirement.
- 3Dr. Marc Tessier-Lavigne has retired as a director, effective September 1, 2023, citing potential conflicts with other business involvements.
- 4Kathryn Guarini, Ph.D., has been elected as a Class III director and appointed to the Audit Committee.
- 5David P. Schenkein, M.D., has been elected as a Class II director and appointed to the Technology Committee.
- 6Both new directors will serve until the 2024 Annual Shareholder Meeting and will be compensated according to the company's standard non-employee director practices.